Actual issues of secondary prevention of liver cancer in Kazakhstan

Niyaz Malayev 1 2, Samat Saparbayev 3, Saule Kubekova 4 * , Nurlan Zhampeissov 5
More Detail
1 Department of Oncology, Marat Ospanov West Kazakhstan Medical University, Aktobe, Kazakhstan
2 Department of General and Thoracic Surgery, National Scientific Medical Center, Astana, Kazakhstan
3 Department of Surgery, Astana Medical University, Astana, Kazakhstan
4 Department of Cardiology, Astana Medical University, Astana, Kazakhstan
5 Department of Radiation Diagnostics and Ultrasound Imaging, National Scientific Medical Center, Astana, Kazakhstan
* Corresponding Author
J CLIN MED KAZ, Volume 20, Issue 6, pp. 66-72. https://doi.org/10.23950/jcmk/13926
OPEN ACCESS 351 Views 372 Downloads
Download Full Text (PDF)

ABSTRACT

Liver cancer is characterized by high mortality and low survival rates in most countries of the world. According to the WHO data, more than 1.3 million people with liver cancer die annually in the world and according to the data of the 9th volume of "Cancer on five continents" - the highest standardized incidence rates are in Korea - 44.9 per 100 thousand population as well as in Thailand, Japan, China. Low rates were in Algeria, India, Belgium and the Netherlands. In Russia 61.5% of patients die of liver cancer progression in the first year after diagnosis [1,2].
Information on the global burden of cancer in 2018 showed that the specific weight of liver cancer in the structure of malignant neoplasms (MN) is 8.2%, and in 2020 - 8.3% [3].  
The worldwide peculiarity of liver cancer is its late diagnosis. Several evidence-based treatment options for liver cancer are currently available: liver transplantation for hepatocellular liver cancer (HCC) (according to the Milan criteria), radiofrequency ablation as a radical treatment option (RFA), chemoembolization for intrahepatic cholangiocarcinoma (TACE), and the administration of Sorafenib as systemic therapy [4].
Current approaches for the treatment of early-stage primary liver cancer are represented by hepatic RFA, and the efficacy of this approach depends on the subjective attentiveness and visual acuity of the clinician. The latest technique used in liver RFA is the hyperspectral imaging which utilize objective assessment [2].
Ultrasound is usually used to detect liver lesions, but the detection rate is low for many reasons, such as clinician skills and technical capabilities. Modern approaches of diagnostic capabilities, such as contrast-enhanced ultrasound integrated imaging (CEUS) and comprehensive ultrasound imaging - contrast-enhanced CT (CECT) or contrast-enhanced MRI (CEMRI) for visualization of focal liver lesions (FLL) - increase the confidence of the interventional physician so it should be recommended for use as a routine procedure [5-6].
The ratio of morbidity and mortality in many countries reaches 91.6%, which represents the third most important cause of cancer deaths [7-9].

CITATION

Malayev N, Saparbayev S, Kubekova S, Zhampeissov N. Actual issues of secondary prevention of liver cancer in Kazakhstan. J CLIN MED KAZ. 2023;20(6):66-72. https://doi.org/10.23950/jcmk/13926

REFERENCES

  • Chekmazov I.A., Ivanikov I.O. et al. Liver cancer: etiology, pathogenesis, results of clinical and epidemiological observation. Evidence-based Gastroenterology. 2019; 8(1):5-15. https://doi.org/10.17116/dokgastro201980115
  • Abdlaty R, Abbass MA, Awadallah AM. Radiofrequency ablation for liver: Comparison between expert eye and hyperspectral imaging assessment. Photodiagnosis Photodyn Ther. 2022; 37:102699. https://doi.org/10.1016/j.pdpdt.2021.102699
  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. https://doi.org/10.3322/caac.21660
  • Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. Liver cancer: Approaching a personalized care. J Hepatol. 2015; 62(1 Suppl):144-56. https://doi.org/10.1016/j.jhep.2015.02.007
  • Bo XW, Xu HX, Wang D, Guo LH, Sun LP, Li XL, Zhao CK, He YP, Liu BJ, Li DD, Zhang K. Fusion imaging of contrast-enhanced ultrasound and contrast-enhanced CT or MRI before radiofrequency ablation for liver cancers. Br J Radiol. 2016; 89(1067):20160379. https://doi.org/10.1259/bjr.20160379
  • Minami Y, Kudo M. Image Guidance in Ablation for Hepatocellular Carcinoma: Contrast-Enhanced Ultrasound and Fusion Imaging. Front Oncol. 2021; 11:593636. https://doi.org/10.3389/fonc.2021.593636
  • Carloni R, Rizzo A, Cusmai A, Palloni A, Federico AD, Marco MD, Massafra R, Fanizzi A, Palmiotti G, Brandi G. Advances in novel systemic therapies for advanced hepatocellular carcinoma. Future Med Chem. 2022; 14(20):1455-1470. https://doi.org/10.4155/fmc-2022-0045
  • Wong KM, King GG, Harris WP. The Treatment Landscape of Advanced Hepatocellular Carcinoma. Curr Oncol Rep. 2022; 24(7):917-927. https://doi.org/10.1007/s11912-022-01247-7
  • Villarruel-Melquiades F, Mendoza-Garrido ME, García-Cuellar CM, Sánchez-Pérez Y, Pérez-Carreón JI, Camacho J. Current and novel approaches in the pharmacological treatment of hepatocellular carcinoma. World J Gastroenterol. 2023; 29(17):2571-2599. https://doi.org/10.3748/wjg.v29.i17.2571